Announcing the launch of Medtronic Neurovascular Co-Lab Platform to accelerate innovation in stroke treatment

New Medtronic Neurovascular Co-Lab Platform drives collaboration and connections among start-ups, physicians, and institutions; aims to improve stroke treatment and access for patients worldwide

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of Medtronic Neurovascular Co-Lab ™ Platform designed to accelerate urgently needed innovation in stroke care and treatment.

Medtronic Neurovascular announces the launch of the Medtronic Neurovascular Co-Lab™ Platform

The company is harnessing its market-leading position and trusted partner reputation to create a platform that will ultimately advance technology concepts that have the highest potential to positively impact millions of stroke patients. Innovators, entrepreneurs, and physicians will be able to collaborate, enhance, and share their breakthrough concepts and products. With the launch of Medtronic Neurovascular Co-Lab Platform, Medtronic is deepening its commitment to advance stroke innovation as the world prepares to recognize World Stroke Day on October 29, 2022 .

"We need to act now to prioritize the best concepts and strongest products to ensure they reach more patients sooner," said Dan Volz , president of the Medtronic Neurovascular business, which is part of the Neuroscience Portfolio. "Clinicians and innovators are passionate about improving stroke care, and the neurovascular technology market is brimming with ideas, improvements, and would-be therapies in need of development. Our platform will provide both an infrastructure and a process to realize viable opportunities on a previously unmatched scale."

Medtronic Neurovascular Co-Lab Platform will help bring neurovascular innovations to life. The process will be both transparent and collaborative, ensuring opportunities advance effectively and responsibly. The platform will be launched on October 29 , World Stroke Day.

"What's fascinating about the neurovascular field is that we still have so much to discover about the brain. Medtronic has always invested in innovative stroke treatment technologies leading the standard of care and advancing the practice of neurosurgery," said Brett Wall , executive vice president and president of the Medtronic Neuroscience Portfolio. "The neurovascular market has enormous growth potential, and we invite innovative start-ups, physicians, venture-capital firms and inventors to collaborate with us as we set out to change stroke care as we know it today. With more than 90,000 employees across 150 countries – combined with our proven record in stroke innovation – Medtronic is positioned well to help address this urgent challenge."

Medtronic Neurovascular Co-Lab Platform is an always-on virtual portal for innovator submissions, which are then assessed and prioritized to determine a potential path forward. Chosen opportunities will be advanced based on their individual needs, including exposing innovators to Medtronic's network of experts, thought leaders and partners for collaboration, clinical study funding, and strategic and directional guidance.

Medtronic welcomes innovations at every stage of development to move them to the next level; however, high-priority opportunities are high-potential, late-stage clinical and commercial-stage products and technology, followed by physician-led improvements to existing products. To learn more, or input a submission, please visit Medtronic Neurovascular Co-Lab Platform at www.medtronic.com/neurovascular-co-lab .

About the stroke challenge
Advancing stroke care is critical and urgent. Globally, 15 million people suffer from stroke annually. Of those, 5 million people die and another 5 million are left permanently disabled. 1 Yet, the second leading cause of death and the third leading cause of disability globally often goes untreated. 2 Most people experience ischemic strokes in which blood flow to the brain is blocked by a clot. Studies indicate that only about 10 to 14 percent receive clot-dissolving treatment that can stop the onset of stroke symptoms. 3

Furthermore, the use of mechanical thrombectomy, a surgical treatment for stroke and the standard of care for large vessel occlusion strokes remains extremely low. In the U.S., the 2019 estimate of thrombectomies was below 40,000, while the number of patients who could benefit from thrombectomy was between 200,000 and 350,000. 4

About the Neurovascular business at Medtronic
With the largest neurovascular technology business in the world, Medtronic Neurovascular led evidence-based medicine in neurointervention with five landmark studies published in The New England Journal of Medicine in 2015 . Its clinical and regulatory leadership and bold approach shaped the current guidelines for treating strokes. 5

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

References:

  1. Stroke, Cerebrovascular accident. World Health Organization, https://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html . Accessed September 6, 2022 .
  2. What we do. World Stroke Organization. https://www.world-stroke.org/what-we-do . Accessed October 6, 2022 .
  3. Skolarus, et al. Marked Regional Variation in Acute Stroke Treatment Among Medicare Beneficiaries. Stroke. (2015) 46: 1890-1896.
  4. The Global Push for Mechanical Thrombectomy in Stroke Care. NeurologyLive, December 2020 , Volume 3, Issue 7. https://www.neurologylive.com/view/the-global-push-for-mechanical-thrombectomy-in-stroke-care
  5. The 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment.

Contacts:




Kelli Lynch

Ryan Weispfenning

Public Relations

Investor Relations

+1-203-500-3328

+1-763-505-4626

(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/announcing-the-launch-of-medtronic-neurovascular-co-lab-platform-to-accelerate-innovation-in-stroke-treatment-301653851.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

MDT
The Conversation (0)
Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. (TSX: PNE) ("Pine Cliff" or the "Company") announces its first quarter 2024 financial and operating results, an operational update and information regarding the annual meeting of shareholders.

First Quarter 2024 Results

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Canadian Natural Resources Limited Announces 2024 First Quarter Results

Canadian Natural's (TSX: CNQ) (NYSE: CNQ) President, Scott Stauth, commented on the Company's first quarter results, "Canadian Natural is a world class company and during our 35 years of operations, we've delivered significant value, including recently reaching a position where, commencing in 2024, we are returning 100% of our free cash flow to our shareholders. Crude oil price forecasts have strengthened for the remainder of 2024, including improvements in West Texas Intermediate ("WTI"), Western Canadian Select ("WCS") and Synthetic Crude Oil ("SCO") pricing over those prices experienced in the first quarter of 2024, driving significant targeted free cash flow generation going forward.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. (TSX: PNE) (OTCQX: PIFYF) ("Pine Cliff" or the "Company") is pleased to announce the appointments of Mr. Daniel Keenan P. Eng to the position of Vice President Exploitation and Mr. Austin Nieuwdorp CA, CPA to the position of Vice President Finance and Controller both effective May 1, 2024.

Mr. Keenan became part of Pine Cliff in 2016. He holds a Bachelor of Mechanical Engineering Degree from the University of Victoria obtained in 2001. Throughout his 20-year career, he has taken on increasingly challenging roles in exploitation, production operations and facilities engineering, culminating in his most recent position as Pine Cliff's Manager of Exploitation. Notably, Mr. Keenan has played a pivotal role in identifying and expanding Pine Cliff's asset portfolio and drilling opportunities, showcasing his leadership and strategic vision.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. (TSX: ACO.X) (TSX: ACO.Y)

2024 ATCO AGM (CNW Group/ATCO Ltd.)

ATCO Ltd. (ATCO) will hold its 57th Annual General Meeting of share owners at 10 a.m. MDT on Wednesday , May 15, 2024. In addition to the formal business of the meeting, attendees will hear management's view of ATCO's full year 2023 and first quarter 2024 operational and financial performance.

At this year's meeting, members of the ATCO executive leadership team will also outline growth strategies and goals for ATCO Structures, ATCO EnPower and ATCO Energy Systems.

Attendees will hear from:

  • Nancy Southern , Chair & Chief Executive Officer
  • Katie Patrick , Executive Vice President, Chief Financial & Investment Officer
  • Adam Beattie , President, ATCO Structures
  • Bob Myles , Chief Operating Officer, ATCO EnPower
  • Wayne Stensby , Chief Operating Officer, ATCO Energy Systems

Share owners and interested parties can view the meeting virtually using Microsoft Teams via this link using a web browser (Chrome, Safari, Edge or Firefox) on a smartphone, tablet or computer. Using Internet Explorer is not recommended as it is no longer supported and may not function properly.

Attendees who are share owners or proxyholders wishing to vote their shares should review the information contained in the ATCO Management Proxy Circular dated March 11, 2024 , beginning on page one.

As a global enterprise ATCO Ltd. and its subsidiary and affiliate companies have approximately 20,000 employees and assets of $25 billion . ATCO is committed to future prosperity by working to meet the world's essential energy, housing, security and transportation challenges. ATCO Structures designs, builds and delivers products to service the essential need for housing and shelter around the globe. ATCO Frontec provides operational support services to government, defence and commercial clients. ATCO Energy Systems delivers essential energy for an evolving world through its electricity and natural gas transmission and distribution, and international operations. ATCO EnPower creates sustainable energy solutions in the areas of renewables, energy storage, industrial water and clean fuels. ATCO Australia develops, builds, owns and operates energy and infrastructure assets. ATCOenergy and Rümi provide retail electricity and natural gas services, home maintenance services and professional home advice that bring exceptional comfort, peace of mind and freedom to homeowners and customers. ATCO also has investments in ports and transportation logistics, the processing and marketing of fly ash, retail food services and commercial real estate. More information can be found at www.ATCO.com .

Investor & Analyst Inquiries:  
Colin Jackson
Senior Vice President, Finance, Treasury & Sustainability
Colin.Jackson@atco.com
(403) 808 2636

Media Inquiries:
Kurt Kadatz
Director, Corporate Communications
Kurt.Kadatz@atco.com
(587) 228 4571

SOURCE ATCO Ltd.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/29/c6613.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces First Quarter 2024 Results, Record Oil Royalty Production

-

PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce its first quarter ("Q1 2024") operating and financial results for the three-month period ended March 31, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation ("Thermo Fisher"), a world leader in supplying life sciences solutions and services.

The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed's Next Generation colorectal cancer screening product. The collaboration will harness Thermo Fisher's powerful technologies, instrumentation and information translation systems to enable Mainz Biomed to develop the proprietary assays for its mRNA-based next-generation CRC screening tests which are redefining standards in early cancer detection. Mainz Biomed's flagship non-invasive test not only targets the early detection of colorectal cancer but also focuses on precancerous lesions, particularly advanced adenomas, demonstrating significant clinical success in both US and European trials.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Present at the Wolfe 2024 Healthcare Conference on November 19, 2024

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Wolfe Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. (EDT).

You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on January 15, 2025, to shareholders of record as of December 13, 2024.

About Thermo Fisher Scientific

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Third Quarter 2024

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

Q3   2024   Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic to announce financial results for its second quarter of fiscal year 2025

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday, November 19, 2024 . A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's second quarter of fiscal year 2025, which ended on Friday, October 25, 2024 .

Medtronic will host a video webcast at 7:00 a.m. CST on November 19, 2024 , to discuss results for its second quarter of full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral renal denervation catheter

The Symplicity blood pressure procedure offers patients a new adjunct approach to lowering blood pressure

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral ™ renal denervation (RDN) catheter, used in the Symplicity ™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025 aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×